We are live on ! Find out more
PAI

Palo Alto Investors Portfolio holdings

AUM $654M
1-Year Est. Return 77.8%
This Fund
S&P 500
This Quarter Est. Return
+16.29%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$2.37B
AUM Growth
+$232M
Cap. Flow
-$6.42M
Cap. Flow %
-0.27%
Top 10 Hldgs %
74.03%
Holding
40
New
2
Increased
10
Reduced
8
Closed
–

Top Buys

Rank Stock Value
1
BIVV
Bioverativ Inc. Common Stock
BIVV
+$12.4M
2
EPZM
Epizyme, Inc
EPZM
+$10.7M
3
INSM icon
Insmed
INSM
+$10.5M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$6.71M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$4.75M

Top Sells

Rank Stock Value
1
SAGE
Sage Therapeutics
SAGE
+$19.3M
2
GILD icon
Gilead Sciences
GILD
+$13.4M
3
UTHR icon
United Therapeutics
UTHR
+$13.4M
4
FOLD
Amicus Therapeutics
FOLD
+$6.89M
5
ABMD
Abiomed Inc
ABMD
+$2.42M

Sector Composition

Rank Sector Weight
1 Healthcare 94.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RIGL icon
26
Rigel Pharmaceuticals
RIGL
$781M
$9.79M 0.41%
385,502
– –
TLPH icon
27
Talphera
TLPH
$72.7M
$4.75M 0.2%
51,636
– –
ALIM
28
DELISTED
Alimera Sciences
ALIM
$4.07M 0.17%
200,920
– –
DRNA
29
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$2.88M 0.12%
500,913
– –
VIRX
30
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$2.25M 0.1%
33,214
– –
CYTK icon
31
Cytokinetics
CYTK
$10.5B
$1.79M 0.08%
123,686
– –
ACGN
32
DELISTED
Aceragen Inc
ACGN
$1.37M 0.06%
4,537
– –
CEMP
33
DELISTED
Cempra, Inc.
CEMP
$1.11M 0.05%
340,320
– –
ZGNX
34
DELISTED
Zogenix, Inc.
ZGNX
$1.03M 0.04%
29,500
– –
TRVN
35
DELISTED
Trevena, Inc.
TRVN
$870K 0.04%
546
– –
ALDR
36
DELISTED
Alder Biopharmaceuticals
ALDR
$789K 0.03%
+64,400
New +$671K
OCGN icon
37
Ocugen
OCGN
$471M
$600K 0.03%
5,049
– –
SPHS
38
DELISTED
Sophiris Bio, Inc.
SPHS
$530K 0.02%
247,000
– –
ARCT icon
39
Arcturus Therapeutics
ARCT
$221M
$276K 0.01%
38,970
– –
SLNO
40
DELISTED
Soleno Therapeutics
SLNO
$220K 0.01%
1,130
-4,520
-80% -$178K
1
2

Similar funds

RRA
Round Rock Advisors Wilton, Connecticut $654M AUM 22.95% 1-Year Est. Return
AG
Alibaba Group Causeway Bay, Hong Kong $653M AUM 16.11% 1-Year Est. Return
BL
BWCP LP Dallas, Texas $656M AUM 41.58% 1-Year Est. Return
PIM
Parker Investment Management Menlo Park, California $659M AUM 52.52% 1-Year Est. Return
ACA
Apis Capital Advisors New York $648M AUM 302.67% 1-Year Est. Return
PCM
Primavera Capital Management George Town, Cayman Islands $648M AUM 6.1% 1-Year Est. Return
HCM
Huber Capital Management El Segundo, California $647M AUM 24.91% 1-Year Est. Return
ACM
Arosa Capital Management Miami Beach, Florida $660M AUM 210.26% 1-Year Est. Return

Palo Alto Investors's Q3 2017 Portfolio in Review

As of Q3 2017, Palo Alto Investors held 40 positions worth $2.37B, up 11% from $2.14B the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Palo Alto Investors's Q3 2017 filing shows 2 new, 10 increased and 8 reduced positions. Its largest new stake was Bioverativ Inc. Common Stock: 211,300 shares worth $12.1M. The largest sale was Sage Therapeutics, an estimated $19.3M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier.

  • Palo Alto Investors's largest Q3 2017 buy was Bioverativ Inc. Common Stock: 211,300 shares worth $12.1M.
  • Palo Alto Investors added most to Epizyme, Inc in Q3 2017, an estimated $10.7M increase.
  • Palo Alto Investors's biggest Q3 2017 reduction was Sage Therapeutics, cutting an estimated $19.3M.
  • Palo Alto Investors's ten largest holdings make up 74% of its $2.37B portfolio in Q3 2017.
  • Palo Alto Investors opened 2 new positions and closed 0 in Q3 2017.
  • Palo Alto Investors's portfolio value rose 11% quarter-over-quarter to $2.37B.

Based on Palo Alto Investors's 13F filing for Q3 2017, filed 14 Nov 2017.